Abstract-The present analysis was undertaken to study the effect of oral contraceptive (OC) use on activated factor VII (FVIIa) in subjects characterized by FVII genotypes, with the further aim of evaluating the role of lipids in this pharmacological interaction. In OC users (nϭ42) and nonusers (nϭ130) Key Words: factor VII Ⅲ activated factor VII Ⅲ phospholipids Ⅲ factor VII genotype S ince the introduction of oral contraceptives (OCs) in the 1960s, epidemiological studies have revealed an association between their use and an increase in the risk of cardiovascular disease (CVD). [1] [2] [3] [4] [5] [6] The most important cardiovascular complications noted were venous thromboembolism, myocardial infarction, and thrombotic stroke, 6 -11 with higher risk and susceptibility in female smokers in the 35ϩ age range. 12 The increased CVD risk has been attributed to the estrogenic component 7, 13 : in fact, it was found to be reduced after the introduction of OCs containing a lower estrogen dose, [13] [14] [15] [16] [17] [18] but recently venous thromboembolism was found to be higher in women using contraceptives containing third-generation compared with second-generation progestogens. 19 -22 The effect of OCs on hemostatis is an increase in the levels of some coagulation factors (factors II, VII [FVII], IX, X, XI, and VIII; von Willebrand factor; and fibrinogen), of protein C, and of protein complexes and fragments related to the activation of coagulation (thrombin-antithrombin complexes and D-dimer); these enhance fibrinolysis and decrease the levels of antithrombin III, protein S, and C4b-binding protein. [23] [24] [25] [26] [27] [28] [29] [30] [31] Concerning FVII, a relationship between FVII levels, the dose of estrogen, [23] [24] [25] [26] [27] [28] 31 and progestogen (norethisterone but not D-norgestrel 32 ) was consistently found. It is difficult, though, to pinpoint whether these changes are due to the estrogen or the progestative compound, and it is still a matter of debate whether the excess CVD risk after the use of OCs is related to the resulting dyslipidemia, the hemostasis changes, or both. Recently, a meta-analysis 33 pointed out the absence of an association between the duration of OC administration and CVD risk; the same analysis showed that the increased risk was limited to the period of OC administration.
S
ince the introduction of oral contraceptives (OCs) in the 1960s, epidemiological studies have revealed an association between their use and an increase in the risk of cardiovascular disease (CVD). [1] [2] [3] [4] [5] [6] The most important cardiovascular complications noted were venous thromboembolism, myocardial infarction, and thrombotic stroke, 6 -11 with higher risk and susceptibility in female smokers in the 35ϩ age range. 12 The increased CVD risk has been attributed to the estrogenic component 7, 13 : in fact, it was found to be reduced after the introduction of OCs containing a lower estrogen dose, [13] [14] [15] [16] [17] [18] but recently venous thromboembolism was found to be higher in women using contraceptives containing third-generation compared with second-generation progestogens. 19 -22 The effect of OCs on hemostatis is an increase in the levels of some coagulation factors (factors II, VII [FVII] , IX, X, XI, and VIII; von Willebrand factor; and fibrinogen), of protein C, and of protein complexes and fragments related to the activation of coagulation (thrombin-antithrombin complexes and D-dimer); these enhance fibrinolysis and decrease the levels of antithrombin III, protein S, and C4b-binding protein. [23] [24] [25] [26] [27] [28] [29] [30] [31] Concerning FVII, a relationship between FVII levels, the dose of estrogen, [23] [24] [25] [26] [27] [28] 31 and progestogen (norethisterone but not D-norgestrel 32 ) was consistently found. It is difficult, though, to pinpoint whether these changes are due to the estrogen or the progestative compound, and it is still a matter of debate whether the excess CVD risk after the use of OCs is related to the resulting dyslipidemia, the hemostasis changes, or both. Recently, a meta-analysis 33 pointed out the absence of an association between the duration of OC administration and CVD risk; the same analysis showed that the increased risk was limited to the period of OC administration.
Because FVII has attracted attention owing to its association with lipids (namely triglycerides [TGs] and cholesterol
[chol]) 34 -44 and is considered a risk factor for CVD, 45, 47 we thought it appropriate to analyze, in a group of women on OCs, the interaction between lipids on the one hand and FVII phenotype and genotype on the other. In fact, recent data published by our group indicate that there is a close relationship between FVII, particularly the activated form (FVIIa), and certain FVII genotypes, 48, 49 and that high phospholipid (PhL) concentrations predict high FVIIa levels. 50 
Methods

Study Population
Of the 501 volunteer subjects enrolled in the "Clotart" study in 5 European countries (France, Italy, the Netherlands, Norway, and Spain), 49, 50 219 (47.7%) were females; of these, 42 were taking OCs. All participants declared themselves to be in good health and free from CVD, diabetes, and cancer. General enrollment criteria were as previously reported. 49, 50 Women on OCs were compared with a control group of 130 women not taking OCs of comparable age range: 21.3 to 50.8 years (median, 32.5) for the women on the OC pill and 19.1 to 50.5 years (median, 33.8) for the controls (in the tables and in the statistical analysis, data were adjusted for age). All the subjects gave their informed consent.
Blood Sampling
Blood for coagulation studies was taken in 5-mL Vacutainer tubes (Becton Dickinson Vacutainer Systems Europe) containing 0.5 mL of 0.129 mol/L buffered sodium citrate. For the lipid assays, tubes without anticoagulant were used; serum was prepared by incubation of blood for Ն2 hours at 37°C. All samples were centrifuged at 2000g for 15 minutes. Sera and plasma were harvested and divided into aliquots in plastic tubes (Sorenson BioScience). Samples were frozen at Ϫ80°C in cryotubes and boxes (CryoStore Systems, Nunc Inc) and subsequently sent on dry ice to the central repository at the coordinating institution (Thrombosis Center, University of Rome) for redistribution. For the genetic evaluation, pellets from the citrated blood samples were harvested in plastic tubes and frozen at Ϫ10°C.
Assay Procedures
FVII coagulation activity (FVIIc) and FVII antigen (FVIIAg) assays were carried out as previously reported. 48 -50 In detail, FVIIc was assayed by an automated 1-stage assay with a recombinant thromboplastin preparation with an international sensitivity index close to 1 (Innovin, Dade). FVIIa was assayed with a commercial kit (Staclot VIIa-rTF, Diagnostica Stago). 51,48 -50 Values were expressed in mU/mL, with 30 mU being equivalent to 1 ng of FVIIa. For FVIIa the standard was a recombinant protein, and for FVIIc and FVIIAg assays, the standard was a locally prepared, pooled plasma (20 males and 20 females). Prothrombin fragment 1ϩ2 (F1ϩ2) was assayed with a commercial kit (Enzygnost F1ϩ2 assay, Dade-Behring).
FVII genetic markers were evaluated as previously reported. 48 -50 Comparisons were made between the most frequent FVII genotypes. The alleles of the polymorphism in the promoter region (5ЈF7) were denominated A2 (single decamer insertion) and A1 (absence of the decamer), and the alleles of the 353 R/Q polymorphism, characterized by a mutation in the second position of the 353 codon, were denominated M1 (codon for arginine) and M2 (codon for glutamine). Tight linkage disequilibrium between the A1 and M1 as well as between the A2 and M2 alleles was found (⌬ values ranging from 0.85 to 0.93), regardless of the population studied. 49 Total chol was determined using a commercial kit (Cholesterol, Du Pont) based on the production of stoichiometric amounts of H 2 O 2 generated by cholesterol esterase and cholesterol oxidase. 52 HDLchol was determined by using the same procedure after precipitation of the other cholesterol-containing lipoprotein fractions by a phosphotungstate solution buffered to pH 5.7 53 (HDL-CHOL Du Pont). LDL-chol was evaluated by the indirect procedure as proposed by Friedewald et al. 54 TGs were assayed by a kinetic NAD-coupled procedure 55 (Triglycerides, Du Pont). Choline-containing PhLs were evaluated by a choline oxidase determination of the amount of choline liberated by phospholipase D 56 (Phospholipids, SGM Italia).
ApoA1 was determined by a turbidimetric end-point measurement using 10 mmol/L PEG and a specific polyclonal antibody 57 (APO A1, Du Pont). Lp(a) was determined by an enzyme immunoassay using a monoclonal anti-kringle IV antibody and a polyclonal anti-Lp(a) antibody conjugated with horseradish peroxidase 58 [Macra Lp(a), Strategic Diagnostic]. Each participating laboratory carried out 1 or more analyses on the entire study population.
Statistical Analysis
The procedures used were from the BMDP software package. The distribution of variables was assessed for deviation from normality, and the appropriate normalizing (logarithmic) transformation was used to analyze the data by parametric methods. Tables were computed on the untransformed data. Parametric ANOVAs (1-way, 2-way) and ANCOVAs (with age as a covariate) were used, including the main effects and interactions in the models. Pearson's linear correlation coefficients were used to detect any association between variables. A fixed multiple linear regression model was fitted to the data to estimate the effect (after adjustment for the effects of age, sex, and country) of high concentrations in each independent lipid variable on the dependent one (FVII parameters). Problems due to colinearity were checked and ruled out during the analysis. The appropriate Student's t tests were performed to assess the significance of correlation and regression coefficients and of differences in coefficients between subgroups.
Results
General Description of the Subject Sample in the "Users" and "Nonusers" Subgroups
In Table 1 , the levels of the variables and the statistical evaluation concerning the data for OC users and nonusers are set out. The following variables were significantly different between users and nonusers: PhLs, TGs, ApoA1, chol, FVIIAg, FVIIc, and HDL-chol.
Influence of FVII Genotypes on FVII Levels in Users and Nonusers
A highly significant difference in FVII levels was noted between the genotypes studied and between OC users and nonusers (Table 2) : women with the A11 M11 genotype had significantly higher values than did those with other genotypes, more so for FVIIa and FVIIc than for FVIIAg. OC users had significantly higher levels of FVII than nonusers. This trend was more apparent with regard to FVIIc and FVIIAg than to FVIIa. F1ϩ2 levels were significantly higher in the subjects with the A11 M11 genotype who were on OCs in comparison with those not taking OCs (1.21 versus 1.10 nmol/L, Fϭ7.4, Pϭ0.008).
Multiple Regression Analysis of the Effect of High Lipid Concentrations on FVII Levels
High PhL concentrations were associated with very high and significant FVIIa and FVIIc levels in OC users ( Table 3) . The difference between users and nonusers was more significant for FVIIa and FVIIc than for FVIIAg. High concentrations of TGs and chol, on the other hand, were found to be consistently associated with insignificant changes of FVII in both users and nonusers.
Multiple Regression Analysis Regarding the Influence of FVII Genotypes on the Interaction Between FVII and PhL
In the A11 M11 genotype, high PhL levels were associated with markedly elevated FVIIa levels in OC users ( Table 4 ). The differences between users and nonusers were highly 
Discussion
This cross-sectional study was carried out using samples taken from healthy subjects enrolled through the use of a questionnaire focusing on the presence of risk factors for CVD. It is worth mentioning that this investigation did not take into account the details of OC use, such as the brand of OC and the duration of OC intake. If this approach is seen as a bias for comparative evaluations concerning the effects of different generations and brands of OC, it is, in our opinion, useful in providing a general outline of the average impact of OCs on subjects observed in outpatient or inpatient clinics. The levels of FVII and the concentrations of lipids in this study are consistent with those described in other reports of women on low-dose or sequential OC pills. In fact, the increase noted in FVII levels represents a well-documented effect of OCs, 14, [25] [26] [27] [28] [29] [30] [31] as does that of chol, TGs, HDL-chol, and apoA1 levels. 32,59 -62 Most of the studies 14, 28, [61] [62] [63] and a recent review 31 have described an increase in FVIIc and FVIIAg levels that was roughly related to the estrogen dose. In a recent report, 30 FVIIa was also assayed, and it was found to be increased. In the present study, while analyzing the total population (Table  1) , we were unable to find a statistically significant difference between users and nonusers. We noted, however, great variation in the FVIIa levels, which could explain the lack of statistical difference between users and nonusers. This prompted us to evaluate the impact of FVII genotypes, the importance of which has been demonstrated in determining FVII levels. 48 -50 The genetic analysis demonstrated that FVIIc and FVIIa levels were much higher in the A11 M11 genotype than in the others. The use of OCs displayed only an additional effect on FVII levels, and the presence of an interaction between OC use and genotype was ruled out (Table 2) .
In a recent report by our group, 50 it was observed that high PhL concentrations were associated with high FVIIa levels. To test the strength of this association in the context of OC use, we carried out a multiple regression analysis. This analysis clearly demonstrated that the major determinants of FVII were PhLs, whose high concentrations were found to be associated with high levels of FVIIc, FVIIa, and FVIIAg, mainly in OC users. This was not the case when high concentrations of TGs and chol were considered in the analysis as independent variables. The fact that FVIIa and FVIIc were more affected by high PhL concentrations than high FVIIAg levels indicates that activation of FVII occurs, together with a meaningful increase of the total FVII mass. This idea is confirmed by the presence of significantly higher F1ϩ2 levels in subjects with the A11 M11 genotype taking OCs compared with those not on OCs.
For methodological reasons, namely, to use a highly reproducible and standardized assay method, we have limited our investigation to the choline-containing PhLs. Other PhLs could also play a role in the interaction between the various lipid fractions and FVII, but the assay of the non-choline-containing PhLs (in particular the acidic ones) is less easily reproducible, and they make up Ͻ10% of the whole PhL concentration, as recently demonstrated by us. 50 It must be emphasized, however, that no conclusive data are available concerning the respective roles of the different PhL compounds in the activation of blood coagulation in general and of FVII in particular.
Because of the possibility of a synergistic effect of the FVII genotype and PhL in OC users, we evaluated the effect of high PhL levels in the different FVII genotypic groups and found that the association between high PhL concentrations and high FVIIa levels was maximal in OC users with the A11 M11 genotype (Table 4 ). These observations would seem to imply that the increase of FVIIa is likely to occur in most of the women on OCs, because the A11 M11 genotype is the most frequent (Ͼ60% of the subjects) 49, 50 and PhLs do increase as a metabolic effect of the estrogenic compound. 64 In conclusion, this study indicates that PhLs and OCs are important environmental determinants of FVIIa levels. It is necessary, though, to ascertain the contribution of their interaction with regard to the thrombotic risk. Other genetic or environmental factors, alone or in combination, can further increase the risk in women on OCs and eventually precipitate the thrombotic event. In fact, recent studies indicate that there is no evidence that FVII activity, per se, can be considered a risk factor for thrombotic events in women. 65, 66 
